NCT07806045
Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Incidence and Severity of Adverse Events and Serious Adverse Events
Timeframe: From first dose through Week 52
Maximum Tolerated Dose and Recommended Phase 2 Dose of Nebulized UC-EVs
Timeframe: Through the first 14-day treatment cycle for each dose cohort
Secondary (14)
Change From Baseline in Health Assessment Questionnaire Score
Change From Baseline in Patient Global Impression of Severity Score
Change From Baseline in St. George's Respiratory Questionnaire Score
Change From Baseline in Leicester Cough Questionnaire Score
Change From Baseline in Forced Vital Capacity at Week 24
Show 9 moreShow less
Percent Change From Baseline in Percent Predicted Diffusing Capacity of the Lung for Carbon Monoxide at Week 24
Change From Baseline in Maximum Pulmonary Nodule Size on Chest HRCT at Week 24
Change From Baseline in Bronchial Wall Thickness on Chest HRCT at Week 24
Change From Baseline in Quantitative Lung Fibrosis and Quantitative Ground-Glass Opacity Scores on Chest HRCT at Week 24
Change From Baseline in Quantitative Interstitial Lung Disease Score on Chest HRCT at Week 24
Change From Baseline in Disease-Related Serologic Markers (for IgG4-RD patients only)
Change From Baseline in Disease-Related Serologic Markers (for SSc patients only)
Change From Baseline in erythrocyte sedimentation rate
Change From Baseline in C-reactive protein
Arms and interventions
UC-EVs armExperimental
This open-label, dose-escalation study with up to three dose levels of nebulized UC-EVs. The maximum tolerated dose (MTD) of nebulized UC-EVs will be determined using dose-escalation 3+3 design. Dose Level 1: 5×10\^9 particles Dose Level 2: 1×10\^10 particles Dose Level 3: 2×10\^10 particles
Biologicals: nebulized human umbilical cord mesenchymal stromal cell-derived extracellular vesicles
Sites
1 site in 1 country
- Peking Union Medical College HospitalBeijing, China